secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-020871
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kintara reports Q3 FY2023 net loss of $3.3M; cash at $3.0M; GBM data expected by year-end
--------------------------------------------------------------------------------

- Net loss $3.3M ($1.94 per share) vs. $5.4M ($5.45) in prior-year quarter; R&D spending down 42%.
- Cash and cash equivalents $3.0M as of March 31, 2023; working capital $3.2M.
- Top-line data from registrational GBM AGILE study for VAL-083 expected before end of calendar 2023.
- Case study data from expanded access program for VAL-083 presented at AACR; REM-001 program paused to conserve cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017023020871/0000950170-23-020871-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017023020871/ktra-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020871

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer